E-LIB Suche - Ergebnisse für: Arkenau, H-T

1

63P Activity and safety of FGFR inhibitors in pan-cancer pa..:

Grochot, R.M. ; Joshi, K. ; Sathanantham, G....
ESMO Open. 9 (2024) - p. 102292 , 2024

Link: https://doi.org/10.1016/..

2

82TiP A modular, open-label, phase I/II study to evaluate t..:

Gianoukakis, A.G. ; Arnold, S.M. ; Kahn, S.A....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S87-S88 , 2023

Link: https://doi.org/10.1016/..

3

Impact of body composition on survival of PD-1/PD-L1-treate..:

Morelli, C. ; Formica, V. ; Roselli, M..
Gastric Cancer. 25 (2022) 6 - p. 1123-1124 , 2022

Link: https://doi.org/10.1007/..

4

A systematic review and meta-analysis of PD-1/PD-L1 inhibit..:

Formica, V. ; Morelli, C. ; Patrikidou, A....
Critical Reviews in Oncology/Hematology. 157 (2021) - p. 103173 , 2021

Link: https://doi.org/10.1016/..

5

Ibrutinib combination therapy for advanced gastrointestinal..:

Oh, D-Y ; Maqueda, MA ; Quinn, DI...
ARTN 1056. , 2024

Link: https://doi.org/10.1186/..

6

First-in-human study of the safety, pharmacokinetics, and p..:

Falchook, G ; Infante, J ; Arkenau, H-T...
ARTN 100797. , 2023

Link: https://repository.icr.a..

7

Phase 1b study of berzosertib and cisplatin in patients wit..:

Telli, ML ; Tolaney, SM ; Shapiro, GI...
NPJ breast cancer, 2022, 8 (1), pp. 45 - ?. , 2022

Link: https://repository.icr.a..

8

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients..:

Meric-Bernstam, F ; Bahleda, R ; Hierro, C...
issn:2159-8274. , 2022

Link: http://hdl.handle.net/11..

9

Quality of life with encorafenib plus cetuximab with or wit..:

Kopetz, S ; Grothey, A ; Van Cutsem, E...
issn:2059-7029. , 2022

Link: http://hdl.handle.net/11..

10

A phase 1b study evaluating the safety and preliminary effi..:

Plummer, R ; Dean, E ; Arkenau, HT...
https://discovery.ucl.ac.uk/id/eprint/10141292/1/1-s2.0-S0169500221006048-main.pdf. , 2022

Link: https://discovery.ucl.ac..

11

Futibatinib, an irreversible FGFR1-4 inhibitor, in patients..:

Meric-Bernstam, F ; Bahleda, R ; Hierro, C...
https://discovery.ucl.ac.uk/id/eprint/10135752/1/2159-8290.CD-21-0697.full.pdf. , 2021

Link: https://discovery.ucl.ac..

12

Pharmacokinetics and safety of capmatinib with food in pati..:

Moreno, V ; Greil, R ; Yachnin, J...
https://discovery.ucl.ac.uk/id/eprint/10129596/1/1-s2.0-S0149291821002009-main.pdf. , 2021

Link: https://discovery.ucl.ac..

13

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advance..:

Naing, A ; Thistlethwaite, F ; De Vries, EGE...
https://discovery.ucl.ac.uk/id/eprint/10133504/1/e002447.full.pdf. , 2021

Link: https://discovery.ucl.ac..

14

Encorafenib Plus Cetuximab as a New Standard of Care for Pr..:

Tabernero, J ; Grothey, A ; Van Cutsem, E...
issn:0732-183X. , 2021

Link: http://hdl.handle.net/11..

15

Immunogenomics of Colorectal Cancer Response to Checkpoint ..:

Bortolomeazzi, M ; Keddar, MR ; Montorsi, L...
Gastroenterology. , 2021

Link: https://qmro.qmul.ac.uk/..